CXF Stock Overview
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Chimerix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$1.42 |
| 52 Week Low | US$0.81 |
| Beta | 1.1 |
| 1 Month Change | -3.95% |
| 3 Month Change | 1.99% |
| 1 Year Change | -17.32% |
| 3 Year Change | -88.24% |
| 5 Year Change | -63.42% |
| Change since IPO | -93.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| CXF | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.4% | -3.1% | 1.8% |
| 1Y | -17.3% | -22.4% | 2.2% |
Return vs Industry: CXF exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: CXF underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| CXF volatility | |
|---|---|
| CXF Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CXF's share price has been volatile over the past 3 months.
Volatility Over Time: CXF's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 72 | Mike Andriole | www.chimerix.com |
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
Chimerix, Inc. Fundamentals Summary
| CXF fundamental statistics | |
|---|---|
| Market cap | €77.11m |
| Earnings (TTM) | -€76.69m |
| Revenue (TTM) | €302.68k |
254.8x
P/S Ratio-1.0x
P/E RatioIs CXF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CXF income statement (TTM) | |
|---|---|
| Revenue | US$324.00k |
| Cost of Revenue | US$68.79m |
| Gross Profit | -US$68.46m |
| Other Expenses | US$13.63m |
| Earnings | -US$82.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -21,130.86% |
| Net Profit Margin | -25,337.96% |
| Debt/Equity Ratio | 0% |
How did CXF perform over the long term?
See historical performance and comparison